

Transfer of Value Report

Publication Date: 29/06/2021 Reporting Year: 2020

			Unique Country Local Identifier (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to Costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for Service and Consultancy (Art. 3.01.1.c & 3.01.2.c)		
Full Name (Art. 1.01) HCPs: City of Principal Practice HCOs: city where registered (Art. 3	Principal Practice				Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommoda tion	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	TOTAL
INDIVIDUAL NAMED DISCL	OSURE - one line per l	HCP (i.e. all transfers o		ar for an individual h	HCP will be summed up: itemiz appropriate)	zation should be a	vailable for the	ndividual R	ecipient or public authorities'	
			MT	N/A						
		OTHER, I	NOT INCLUDED AE	BOVE - where inforn	nation cannot be disclosed on	an individual basis	s for legal reaso	ons		
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02				N/A	N/A					
Number of Recipients in aggregate disclosure - Art. 3.02				N/A	N/A					
% of number of Recipients in the aggreate disclosure in the total number of Recipients disclosed - Art. 3.02				N/A	N/A					
INDIVIDUAL NAMED DISCLOS	JRE - one line per HCC	O (i.e. all transfers of va	lue during a vear fo	or an individual HCC) will be summed up: itemizati	on should be avail	able for the indi	vidual Reci	pient or public authorities' consultation	on only, as appropriate
		(g . ,							у,
		OTHER, I	NOT INCLUDED AE	BOVE - where inform	nation cannot be disclosed on	an individual basis	s for legal reaso	ns		
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02			N/A	N/A						
Number of Recipients in aggregate disclosure - Art. 3.02			N/A	N/A						
% of number of Recipients in the Art. 3.02	aggreate disclosure in	the total number of Red	ipients disclosed -	N/A	N/A					
				AGGF	REGATE DISCLOSURE					
Transfers of Value re Research & Development as defined - Article 3.04										N/

1/1 Amgen CopyRight